Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 2/20 | 0.40 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2246362 | 0.86 | ENPEP (0.47) | ENPEPGABRR1CYP1A2BLM | |
| SCHEMBL1171085 | 0.86 | ENPEP (0.47) | ENPEPGABRR1CYP1A2BLM | |
| SCHEMBL1170965 | 0.86 | ENPEP (0.47) | ENPEPGABRR1CYP1A2BLM | |
| SCHEMBL16536081 | 0.82 | RNPEP (0.35) | GABRR1CYP1A2 | |
| SCHEMBL1171017 | 0.82 | RNPEP (0.35) | GABRR1CYP1A2 | |
| SCHEMBL28601727 | 0.82 | GABRR1 (0.33) | GABRR1CYP1A2 | |
| SCHEMBL28601694 | 0.81 | ACE2 (0.42) | GABRR1CYP1A2BLM | |
| SCHEMBL29507144 | 0.81 | ENPEP (0.42) | ENPEPGABRR1CYP1A2BLM | |
| SCHEMBL690292 | 0.81 | ENPEP (0.42) | ENPEPGABRR1CYP1A2BLM | |
| Lactic Acid SCHEMBL28444410 | 0.80 | TP53 (0.48) | GABRR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624279-B2 | Quantum dot-containing polymerizable composition, cured product, wavelength conversion member, backlight unit, and liquid crystal display device | FUJIFILM CORPORATION (JP) | 2026-05-12 | — | — | US | disclosed |
| EP-4703778-A1 | WAVELENGTH CONVERSION SHEET, BACKLIGHT, AND LIQUID CRYSTAL DISPLAY DEVICE | Dai Nippon Printing Co., Ltd. (JP) | 2026-03-04 | — | — | EP | disclosed |
| US-12565548-B2 | Compound, polymerizable composition, and cured product | FUJIFILM CORPORATION (JP) | 2026-03-03 | — | — | US | disclosed |
| EP-4202505-B1 | BARRIER FILM, AND WAVELENGTH CONVERSION SHEET, BACKLIGHT, AND LIQUID CRYSTAL DISPLAY DEVICE IN WHICH SAME IS USED, AS WELL AS METHOD FOR SELECTING BARRIER FILM | DAINIPPON PRINTING CO LTD (JP) | 2026-02-18 | — | — | EP | disclosed |
| EP-4201667-B1 | BARRIER FILM, AND WAVELENGTH CONVERSION SHEET, BACK LIGHT, AND LIQUID CRYSTAL DISPLAY DEVICE WHICH USE SAME | DAINIPPON PRINTING CO LTD (JP) | 2025-12-17 | — | — | EP | disclosed |
| US-12496802-B2 | Barrier film, wavelength conversion sheet using same, backlight and liquid crystal display device | DAI NIPPON PRINTING CO., LTD. (JP) | 2025-12-16 | — | — | US | disclosed |
| US-12492293-B2 | Multi-component systems for preparing foamed products | ARKEMA FRANCE (FR) | 2025-12-09 | — | — | US | disclosed |
| EP-4202506-B1 | BARRIER FILM, WAVELENGTH CONVERSION SHEET USING SAME, BACKLIGHT AND LIQUID CRYSTAL DISPLAY DEVICE | DAINIPPON PRINTING CO LTD (JP) | 2025-11-26 | — | — | EP | disclosed |
| EP-4579289-A1 | WAVELENGTH CONVERSION SHEET, AND BACKLIGHT AND LIQUID CRYSTAL DISPLAY DEVICE USING SAME | Dai Nippon Printing Co., Ltd. (JP) | 2025-07-02 | — | — | EP | disclosed |
| US-12158662-B2 | Barrier film for wavelength conversion sheet, wavelength conversion sheet, backlight, and liquid crystal display device using barrier film, and method for selecting barrier film for wavelength conversion sheet | DAI NIPPON PRINTING CO., LTD. (JP) | 2024-12-03 | — | — | US | disclosed |
| EP-2143739-A1 | URETHANE COMPOUND, CURABLE COMPOSITION CONTAINING THE SAME, AND CURED PRODUCT OF THE COMPOSITION | Showa Denko K.K. (JP) | 2010-01-13 | — | — | EP | disclosed |
| US-7569327-B2 | Curable polymer compound | SHOWDA DENKO K.K. (JP) | 2009-08-04 | — | — | US | disclosed |
| EP-2055726-A1 | THIOURETHANE COMPOUND AND PHOTOSENSITIVE RESIN COMPOSITION | Showa Denko K.K. (JP) | 2009-05-06 | — | — | EP | disclosed |
| US-20090023831-A1 | Curable Composition Containing Thiol Compound | SHOWA DENKO K.K. (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1983017-A1 | CURABLE COMPOSITION CONTAINING THIOL COMPOUND | Showa Denko K.K. (JP) | 2008-10-22 | — | — | EP | disclosed |
| EP-1629046-B1 | CURABLE POLYMER COMPOUND | SHOWA DENKO KK (JP) | 2008-05-14 | — | — | EP | disclosed |
| US-7341828-B2 | Thiol compound, photopolymerization initiator composition and photosensitive composition | SHOWA DENKO K.K. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20070021571-A1 | Curable polymer compound | SHOWA DENKO K.K. (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20060079593-A1 | Hexaarylbiimidazole compounds and photopolymerization initiator compositions containing the same | SHOWA DENKO K.K. (JP) | 2006-04-13 | — | — | US | disclosed |
| US-20050153231-A1 | Thiol compound, photopolymerization initiator composition and photosensitive composition | SHOWA DENKO K.K. (JP) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624279-B2 | Quantum dot-containing polymerizable composition, cured product, wavelength conversion member, backlight unit, and liquid crystal display device | NLRP1, NLRP3, ALAD | ENPEP 2350/4885GABRR1 3818/4885CYP1A2 2501/4885 |
| US-12565548-B2 | Compound, polymerizable composition, and cured product | SEM1, PSMA1, RER1 | ENPEP 3904/4885GABRR1 926/4885CYP1A2 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.